Revolutionary Technology

Revolutionary Technology

The Staccato system enables rapid onset of action for many drugs.

Simple and Intuitive

Simple and Intuitive

The Staccato system is breath actuated, and a patient simply inhales to administer the drug dose.

Fast-Acting, Non-Invasive Treatment

Fast-Acting, Non-Invasive Treatment

Unlike injections, the Staccato system is noninvasive.

Improved Patient Therapy

Improved Patient Therapy

Products for the treatment of acute and intermittent conditions.

Unique Therapeutic Effect

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions.

See Staccato® in action

Product Pipeline

We have already demonstrated that more than 200 FDA-approved compounds are feasible for delivery by the Staccato® system. Currently we have six development programs focused on six acute and intermittent conditions.

More about our Products

Recent News

  • May 10, 2012
    Alexza Reports 2012 First Quarter Financial Results and Provides Business Update

  • May 3, 2012
    Alexza Receives Complete Response Letter for Adasuve™ NDA

  • April 23, 2012
    Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012

Noteworthy

Phase 3 Clinical Trial Data Published
British Journal of Psychiatry
(353KB PDF)

Read the article
View other publications

Building a Commercial Infrastructure

As our development pipeline grows and our clinical candidates advance in the development process, we have begun building a commercial infrastructure to support what we hope will be a growing portfolio of approved pharmaceutical products.

More on Our Growing Business

Latest Publications

Bipolar Disorders

Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine
Kwentus J, Riesenberg RA, Marandi M, Manning RA, Allen MH, Fishman RS, Spyker DA, Kehne JH, Cassella JV
2012: 14: 31-40

View the paper online

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Assessing the Temperature of Thermally Generated Inhalation Aerosols
Peter D. Noymer, Dan J. Myers, James V. Cassella, Ryan Timmons
February 2011
24(1): 11-15

The British Journal of Psychiatry

Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine
Michael D. Lesem, MD et al
2011

Read the paper

Journal of Clinical Psychiatry

Efficacy and Safety of Loxapine for Inhalation in the Treatment of Agitation in Patients with Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial
Michael H. Allen, MD et al
2011

Journal of Pharmaceutical and Biomedical Analysis

Forced Degradation of Fentanyl: Identification and Analysis of Impurities and Degradants
July 29, 2010
Garg et al

Journal of Aerosol Medicine and Pulmonary Drug Delivery

In Vitro Aerosol Deposition in the Oropharyngeal Region for Staccato Loxapine

Respiratory Drug Delivery 2010

The Staccato System: Inhaler Design Characteristics for Rapid Treatment of CNS Disorders

View the paper online

Future Neurology

Inhaled Loxapine for Acute Agitation in Schizophrenia and Bipolar Disorder

View the paper online

APA 2009 Abstract

Inhaled Loxapine Rapidly Improves Acute Agitation in Patients with Bipolar Disorder

View the abstract (156k PDF)

APA 2009 Abstract

Inhaled Loxapine Rapidly Improves Acute Agitation in Schizophrenic Patients

View the abstract (172k PDF)